Cover Story
Earlier this year, when FDA approved Merck's PD-1 inhibitor Keytruda (pembrolizumab) for “site-agnostic” indications, it raised new questions that will likely shape the future of oncology:
In Brief
Drugs & Targets
Trending Stories
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- My bad: I left out Fox Chase
- Edward Copeland, surgeon and breast cancer expert, dies at 86
- NCI creates Cancer Equity Leaders group to improve cancer health equity
- Pooled analysis questions reliability of an endpoint used in multi-cancer detection trials